Company Description
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally.
The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.
It distributes its products through general line and specialty distributor; international distributors; and national direct marketing network.
Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
| Country | United States |
| Founded | 1994 |
| IPO Date | May 4, 2001 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 227 |
| CEO | Thomas Shaw |
Contact Details
Address: 511 Lobo Lane Little Elm, Texas 75068-5295 United States | |
| Phone | 972 294 1010 |
| Website | retractable.com |
Stock Details
| Ticker Symbol | RVP |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000946563 |
| CUSIP Number | 76129W105 |
| ISIN Number | US76129W1053 |
| Employer ID | 75-2599762 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Shaw | Founder, Chairman, President and Chief Executive Officer |
| John W. Fort III | Vice President, Chief Financial Officer, Principal Accounting Officer,Treasurer and Director |
| Lawrence G. Salerno | Director of Operations |
| Michele M. Larios Esq. | Vice President, General Counsel and Secretary |
| Russell B. Kuhlman | Vice President of Sales Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 8-K | Current Report |
| May 21, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| Apr 11, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | SCHEDULE 13D/A | Filing |